ES2181805T3 - Compuestos quimicos. - Google Patents

Compuestos quimicos.

Info

Publication number
ES2181805T3
ES2181805T3 ES95941214T ES95941214T ES2181805T3 ES 2181805 T3 ES2181805 T3 ES 2181805T3 ES 95941214 T ES95941214 T ES 95941214T ES 95941214 T ES95941214 T ES 95941214T ES 2181805 T3 ES2181805 T3 ES 2181805T3
Authority
ES
Spain
Prior art keywords
enzyme
invested
interaction
muted
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95941214T
Other languages
English (en)
Inventor
Christopher John Uni Taylorson
Hendrikus Johannes Eggelte
Antonio Advance Tarragona-Fiol
Brian Robert Rabin
Francis Thomas Boyle
John Frederick Hennam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2181805(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2181805T3 publication Critical patent/ES2181805T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • External Artificial Organs (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

SISTEMAS MEJORADOS PARA TERAPIA DE PRODROGAS DE ENZIMA APUNTADA, ESPECIALMENTE TERAPIA DE PRODROGA DE ENZIMA DIRIGIDA DE ANTICUERPO (ADEPT), EN LA QUE LA ENZIMA USADA ES UNA FORMA MUTADA DE UNA ENZIMA HUESPED EN LA QUE LA ENZIMA HUESPED NATURAL, TAL COMO LA RIBONUCLEASA, RECONOCE SU SUSTRATO NATURAL POR UNA INTERACCION DE UN PAR DE IONES Y SU INTERACCION SE INVIERTE ("POLARIDAD INVERTIDA") EN EL DISEÑO DE ENZIMA MUTADA Y PRODROGA COMPLEMENTARIA.
ES95941214T 1994-12-23 1995-12-21 Compuestos quimicos. Expired - Lifetime ES2181805T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2181805T3 true ES2181805T3 (es) 2003-03-01

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95941214T Expired - Lifetime ES2181805T3 (es) 1994-12-23 1995-12-21 Compuestos quimicos.

Country Status (23)

Country Link
US (1) US5985281A (es)
EP (1) EP0806964B1 (es)
JP (1) JP3805365B2 (es)
KR (1) KR100270650B1 (es)
CN (1) CN1095677C (es)
AT (1) ATE222124T1 (es)
AU (1) AU701916B2 (es)
BR (1) BR9510490B1 (es)
CA (1) CA2205091A1 (es)
CZ (1) CZ195297A3 (es)
DE (1) DE69527805T2 (es)
ES (1) ES2181805T3 (es)
FI (1) FI972683A0 (es)
HU (1) HUT77450A (es)
IL (1) IL116511A0 (es)
MX (1) MX9704575A (es)
NO (1) NO972882L (es)
NZ (1) NZ297529A (es)
PL (1) PL184031B1 (es)
RU (1) RU2189251C2 (es)
SK (1) SK80997A3 (es)
TR (1) TR199501654A2 (es)
WO (1) WO1996020011A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707689B2 (en) * 1995-08-16 1999-07-15 Astrazeneca Ab Mutated Carboxypeptidase B enzyme conjugated to a tumour targeted antibody for use in Antibody Directed Enzyme Prodrug Therapy
TW406454B (en) 1996-10-10 2000-09-21 Berg Tech Inc High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
EP1113819B1 (en) * 1998-09-18 2011-02-23 Immunomedics, Inc. Antibody directed enzyme prodrug therapy (adept) with glucuronidase
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
KR20020073127A (ko) * 1999-09-17 2002-09-19 겐자임 트랜스제닉스 코포레이션 형질전환에 의하여 생성된 융합 단백질
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
AU2003298787A1 (en) * 2002-11-27 2004-06-23 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
ES2417147T3 (es) * 2005-10-21 2013-08-06 Revo Biologics, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2037954A4 (en) * 2006-06-20 2011-09-14 Janssen Pharmaceutica Nv METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE
EP2792670A1 (en) 2006-10-03 2014-10-22 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
EP2279003A4 (en) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
EP0625205A1 (en) * 1992-01-30 1994-11-23 Genzyme Limited Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
EP0806964A1 (en) 1997-11-19
AU4269796A (en) 1996-07-19
DE69527805D1 (de) 2002-09-19
TR199501654A2 (tr) 1996-07-21
PL184031B1 (pl) 2002-08-30
AU701916B2 (en) 1999-02-11
DE69527805T2 (de) 2003-04-24
JPH10511547A (ja) 1998-11-10
IL116511A0 (en) 1996-07-23
JP3805365B2 (ja) 2006-08-02
EP0806964B1 (en) 2002-08-14
CN1171054A (zh) 1998-01-21
CZ195297A3 (en) 1997-12-17
RU2189251C2 (ru) 2002-09-20
CN1095677C (zh) 2002-12-11
TR199501654A3 (es) 1996-07-21
CA2205091A1 (en) 1996-07-04
US5985281A (en) 1999-11-16
MX9704575A (es) 1997-10-31
HUT77450A (hu) 1998-04-28
NO972882D0 (no) 1997-06-20
FI972683A7 (fi) 1997-06-19
FI972683L (fi) 1997-06-19
SK80997A3 (en) 1998-02-04
BR9510490A (pt) 1998-01-13
NO972882L (no) 1997-08-19
WO1996020011A1 (en) 1996-07-04
FI972683A0 (fi) 1997-06-19
ATE222124T1 (de) 2002-08-15
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
NZ297529A (en) 1999-07-29
BR9510490B1 (pt) 2010-10-05

Similar Documents

Publication Publication Date Title
DE69632630D1 (de) Enzym mit aminopeptidaseactivität
DK0774005T3 (da) Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi
ES2097781T3 (es) Metodo y composicion para la determinacion de iones cloruro en fluidos.
TR199701705T1 (xx) Trigliserid ya�lar�n i�lenmesinde hareketsiz enzim ve kullan�m�.
BR0211551A (pt) Controle de desenvolvimento de biofilmes em água de processo industrial
LU92977I2 (fr) Odomzo, sonifégib et ses sels, en particulier son phosphate
ES2081857T3 (es) Nuevos inhibidores de alpha-glucosidasa.
BR0209466A (pt) Dispositivo, sistema e método para suprir pelo menos um agente ativo a uma superfìcie corporal localizada, e, método para produzir um dispositivo para suprimento de pelo menos um agente ativo a uma superfìcie corporal localizada
TR200103216T2 (tr) Pirimidinon bileşimleri
DE69605184D1 (de) Verabreichung einer substanz in den mund
AR007218A1 (es) Aparato y metodo para la generacion y utilizacion de iones ferricos.
DE69419473D1 (de) Peptidylderivate als inhibitoren von metalloproteinase
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
TR199800815A2 (en) S�lfonilaminokarbonasitler.
ES2166010T3 (es) Produccion de acrilato de amonio.
ATE346144T1 (de) Enzym mit galaktanaseaktivität
MX9704575A (es) Compuestos quimicos.
EP1179183A4 (en) METHOD FOR IDENTIFYING PRENNEOPLASTIC AND NEOPLASTIC STADIAS IN MAMMALS
PT996709E (pt) Inibidores de enzimas celuloliticas, xilanoliticas e betaglucanoliticas
ES2183955T3 (es) Uso de mananasas como agentes de control del cieno.
ES2183313T3 (es) Carbonatos para la generacion de aldehidos y/o cetonas.
ES2079442T3 (es) Oxidacion enzimatica mejorada de cef c a acido glutaril-7-amino-cefalosporanico.
DE60222390D1 (de) Verbessertes in-vitro-synthesesystem
BR9400771A (pt) Processo para a preparação de um meio aquoso de nicotinaldeído e processo para a preparação de um composto
NO180643C (no) Alkalisk pullulanase Y med <alfa>-amylaseaktivitet og en biologisk renkultur av Bacillus sp. mikroorganisme som produserer denne